1. Home
  2. GPATU vs PHIO Comparison

GPATU vs PHIO Comparison

Compare GPATU & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPATU
  • PHIO
  • Stock Information
  • Founded
  • GPATU N/A
  • PHIO 2011
  • Country
  • GPATU
  • PHIO United States
  • Employees
  • GPATU N/A
  • PHIO 5
  • Industry
  • GPATU
  • PHIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPATU
  • PHIO Health Care
  • Exchange
  • GPATU NYSE
  • PHIO Nasdaq
  • Market Cap
  • GPATU N/A
  • PHIO 8.6M
  • IPO Year
  • GPATU N/A
  • PHIO N/A
  • Fundamental
  • Price
  • GPATU $10.70
  • PHIO $1.78
  • Analyst Decision
  • GPATU
  • PHIO Strong Buy
  • Analyst Count
  • GPATU 0
  • PHIO 1
  • Target Price
  • GPATU N/A
  • PHIO $4.00
  • AVG Volume (30 Days)
  • GPATU N/A
  • PHIO 1.1M
  • Earning Date
  • GPATU N/A
  • PHIO 05-27-2025
  • Dividend Yield
  • GPATU N/A
  • PHIO N/A
  • EPS Growth
  • GPATU N/A
  • PHIO N/A
  • EPS
  • GPATU N/A
  • PHIO N/A
  • Revenue
  • GPATU N/A
  • PHIO N/A
  • Revenue This Year
  • GPATU N/A
  • PHIO N/A
  • Revenue Next Year
  • GPATU N/A
  • PHIO N/A
  • P/E Ratio
  • GPATU N/A
  • PHIO N/A
  • Revenue Growth
  • GPATU N/A
  • PHIO N/A
  • 52 Week Low
  • GPATU N/A
  • PHIO $0.97
  • 52 Week High
  • GPATU N/A
  • PHIO $9.79
  • Technical
  • Relative Strength Index (RSI)
  • GPATU N/A
  • PHIO 47.26
  • Support Level
  • GPATU N/A
  • PHIO $1.70
  • Resistance Level
  • GPATU N/A
  • PHIO $2.09
  • Average True Range (ATR)
  • GPATU 0.00
  • PHIO 0.17
  • MACD
  • GPATU 0.00
  • PHIO -0.04
  • Stochastic Oscillator
  • GPATU 0.00
  • PHIO 20.00

About GPATU GP-ACT III ACQUISITION CORP

GP-Act III Acquisition Corp is a blank check company.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Share on Social Networks: